The inclusion of viral proteins in these novel VLP conjugate vaccines provides foreign CD4+ T-cell help, which is especially important for tumour antigens that either fail to induce CD4+ T-cells or where such T cells have been anergized [7]. Here, CD4 is linked to neoplasm.